Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMDW 57 FCF Margin % is -8.59% as of Jun. 2026. GuruFocus rates BTMDW with a GF Score™ of 57/100. The stock has 2 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Biote ranks better than 71.6% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biote's Free Cash Flow for the
three
months ended in Jun. 2026 was $-3.80 Mil. Biote's Revenue for the
three
months ended in Jun. 2026 was $44.23 Mil. Therefore, Biote's FCF Margin % for the quarter that ended in Jun. 2026 was -8.59%.
The historical rank and industry rank for Biote's FCF Margin % or its related term are showing as below:
During the past 7 years, the highest FCF Margin % of Biote was 21.53%. The lowest was -6.67%. And the median was 19.42%.
BTMDW's FCF Margin % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 3.38 * Ranked among companies with meaningful FCF Margin % only.
The historical data trend for Biote's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTMDW vs DCGO, PIII, CCEL: FCF Margin % Comparison
For the Medical Care Facilities subindustry, Biote's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biote's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMDW) has a FCF Margin % of -8.59% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biote and its competitors. According to the industry distribution chart, Biote ranks #190 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 28.4%.
Is Biote's FCF Margin % too high?
Biote's current FCF Margin % is -8.59%. Based on the distribution chart, Biote ranks #190 out of 669 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Biote has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Biote's FCF Margin % compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #190 out of 669 companies for FCF Margin %. This puts Biote in the upper half of its industry. The industry median FCF Margin % is 3.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.38, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current FCF Margin % is -8.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Biote (BTMDW) has a current FCF Margin % of -8.59%. The current FCF Margin % is -8.59%. Biote's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biote (BTMDW), the current FCF Margin % is -8.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
57GF Score
Get the complete analysis for BTMDW
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMDW has been successfully added to your 
